Renaissance Capital logo

Eiger Biopharmaceuticals (Celladon) Acquired, Nasdaq: EIGR

Developing a first-in-class gene therapy for patients with systolic heart failure.

Industry: Health Care

First Day Return: +2.3%

Developing a first-in-class gene therapy for patients with systolic heart failure.
IPO Data
IPO Date 01/29/2014
Offer Price IPO Intelligence Only
Price Range IPO Intelligence Only
Offer Shares (mm) IPO Intelligence Only
Deal Size ($mm) $44
Lock-Up Date IPO Intelligence Only
Street Research IPO Intelligence Only
Underwriters
IPO Intelligence Only
Company Data
Headquarters San Diego, CA, United States
Founded 2000
Employees at IPO 15
Website www.celladon.net

Eiger Biopharmaceuticals (Celladon) (EIGR) Performance

Created with Highcharts 10.3.2Chart context menuEIGR vs. IPO Index (IPOUSA)20152016201720182019202020212022202320242025-100%0%+ 100%+ 200%+ 300%View 5 days5dView 1 month1mView 3 months3mView year to dateYTDView 1 year1yView allAllRenaissance IPO IndexOur ETF tracks the IPO Index